PMID- 37406296
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240106
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 148
IP  - 1
DP  - 2024 Jan 1
TI  - Trichorhinophalangeal Syndrome Type 1 Is a Highly Sensitive and Specific Marker 
      for Diagnosing Triple-Negative Breast Carcinomas on Cytologic Samples.
PG  - e1-e8
LID - 10.5858/arpa.2022-0411-OA [doi]
AB  - CONTEXT.-: Definitive diagnosis of metastatic triple-negative breast carcinoma 
      (TNBC) is challenging on cytologic samples. Recent studies demonstrated that 
      trichorhinophalangeal syndrome type 1 (TRPS1) is a highly sensitive and specific 
      marker for diagnosing breast carcinomas, including TNBC, on surgical specimens. 
      OBJECTIVE.-: To evaluate TRPS1 expression in TNBCs on cytologic samples and a 
      large series of nonbreast tumors on tissue microarray sections. DESIGN.-: 
      Immunohistochemical (IHC) analysis of TRPS1 and GATA-binding protein 3 (GATA3) 
      was performed on 35 TNBC cases on surgical specimens, and 29 consecutive TNBC 
      cases on cytologic specimens. IHC analysis of TRPS1 expression was also performed 
      on 1079 nonbreast tumors on tissue microarray sections. RESULTS.-: Of the 
      surgical specimens, 35 of 35 TNBC cases (100%) were positive for TRPS1, all with 
      diffuse positivity, whereas 27 of 35 (77%) were positive for GATA3, with diffuse 
      positivity in 7 cases (26%). Of the cytologic samples, 27 of 29 TNBC cases (93%) 
      were positive for TRPS1, with diffuse positivity in 20 cases (74%), whereas 12 of 
      29 (41%) were positive for GATA3, with diffuse positivity in 2 cases (17%). Of 
      the nonbreast malignant tumors, TRPS1 expression was seen in 9.4% (3 of 32) of 
      melanomas, 10.7% (3 of 28) of small cell carcinomas of the bladder, and 9.7% (4 
      of 41) of ovarian serous carcinomas. CONCLUSIONS.-: Our data confirm that TRPS1 
      is a highly sensitive and specific marker for diagnosing TNBC cases on surgical 
      specimens as reported in the literature. In addition, these data demonstrate that 
      TRPS1 is a much more sensitive marker than GATA3 in detecting metastatic TNBC 
      cases on cytologic samples. Therefore, inclusion of TRPS1 in the diagnostic IHC 
      panel is recommended when a metastatic TNBC is suspected.
CI  - (c) 2024 College of American Pathologists.
FAU - Lynn, Terrance J
AU  - Lynn TJ
AD  - From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania.
FAU - Shi, Jianhui
AU  - Shi J
AD  - From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania.
FAU - Liu, Haiyan
AU  - Liu H
AD  - From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania.
FAU - Monaco, Sara E
AU  - Monaco SE
AD  - From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania.
FAU - Prichard, Jeffrey W
AU  - Prichard JW
AD  - From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania.
FAU - Lin, Fan
AU  - Lin F
AD  - From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, 
      Pennsylvania.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (TRPS1 protein, human)
RN  - 0 (Repressor Proteins)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Triple Negative Breast Neoplasms/diagnosis/pathology
MH  - Biomarkers, Tumor/analysis
MH  - Immunohistochemistry
MH  - *Breast Neoplasms/pathology
MH  - Urinary Bladder/metabolism
MH  - GATA3 Transcription Factor/analysis
MH  - Repressor Proteins
EDAT- 2023/07/05 19:12
MHDA- 2024/01/02 11:47
CRDT- 2023/07/05 16:23
PHST- 2023/03/29 00:00 [accepted]
PHST- 2024/01/02 11:47 [medline]
PHST- 2023/07/05 19:12 [pubmed]
PHST- 2023/07/05 16:23 [entrez]
AID - 494154 [pii]
AID - 10.5858/arpa.2022-0411-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2024 Jan 1;148(1):e1-e8. doi: 10.5858/arpa.2022-0411-OA.